Indica Labs and Lunit enters into alliance for digital pathology AI workflows

Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution

USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline

Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology

Moderna and Merck announce an investigational individualized neoantigen therapy

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients

TransCure bioServices expands their team to lead the way in animal welfare

The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use

AIIA hosts walkthrough for Working Group of C20 on Integrated Holistic Health

MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Bridgewest Group launches new sterile injectable CDMO NovaCina